Ultrasound-guided radiofrequency ablation (RFA) as a non-invasive treatment has once been described as one of the most disrupting technologies in the field of thyroid surgery. It has been increasingly being used as an alternative to surgery in patients with single, symptomatic benign thyroid nodule. The agenda of the present talk are first to describe how RFA is being carried out as an outpatient procedure and to examine the current evidence supporting the use of RFA. Also, the talk will be discussing the current role and limits of RFA as a non-invasive treatment for low-risk papillary thyroid cancers and other non-nodular thyroid diseases and what role RFA may play in the future from an endocrine surgeon’s perspective.